RPT 1G
Alternative Names: RPT-1GLatest Information Update: 27 May 2025
At a glance
- Originator Remedy Plan Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies
- Preclinical Solid tumours
Most Recent Events
- 13 May 2025 Remedy Plan Therapeutics plans a phase I/II trial for Acute myeloid leukemia and Myelodysplastic syndromes (Monotherapy, Combination-therapy) in second half of 2025 (PO, Capsule)
- 10 Dec 2024 Pharmacodynamics data from preclinical trials in Haematological malignancies released byRemedy Plan Therapeutics ,
- 07 Dec 2024 Adverse events and pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)